- Home
- GOSS vs EBS Comparison
GOSS vs EBS Comparison
Compare GOSS & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | EBS |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.7M | 595.6M |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | GOSS | EBS |
|---|---|---|
| Price | $0.50 | $8.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $4.91 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 27.3M | 1.0M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 78.81 | ★ 125.83 |
| EPS | N/A | ★ 0.93 |
| Revenue | $114,701,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | $29.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $4.02 |
| 52 Week High | $3.87 | $14.06 |
Technical Indicators
Market Signals| Indicator | GOSS | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 23.06 | 30.73 |
| Support Level | $0.33 | $7.66 |
| Resistance Level | $1.23 | $9.68 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 8.98 | 16.44 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.